+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are conducting a global Phase III clinical trial to evaluate the long-term effects of ASC30, an oral medication taken once daily, in adults with obesity or overweight who also have weight-related health conditions but do not have type 2 diabetes. The study aims to compare the efficacy, safety, and tolerability of three different maintenance doses of ASC30 against a placebo. This randomized, double-blind, placebo-controlled trial focuses on assessing body weight changes and related health measures over a lengthy period. Participants in this trial will be randomly assigned to one of four groups three groups receive different doses of ASC30 tablets daily, and one group receives matching placebo tablets daily. The treatment period is planned to last 72 weeks, during which participants will take their assigned oral tablets once a day. The study carefully monitors participants throughout the treatment phase to evaluate the effects of the medication compared to placebo. During the trial, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood glucose, cholesterol, insulin, and other metabolic markers from baseline through week 72. Researchers will also track safety and tolerability over this period. Participants can expect scheduled visits and evaluations to monitor changes in their health and response to the study medication over the roughly 1.5-year treatment duration.

Age: 18Years +All GendersPhase 3
122 locations
C

Actively Recruiting

Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.

Age: 18Years +All GendersPhase 3
299 locations
T

Actively Recruiting

Researchers are evaluating the effects of nucresiran compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy, a condition involving abnormal protein buildup in the heart. This study aims to assess whether nucresiran can reduce deaths from any cause and cardiovascular events, and also improve patient-reported health status and quality of life. The trial is a Phase 3, randomized, double-blind study focused on treatment outcomes. Participants will be randomly assigned to receive either nucresiran 300 mg or a placebo, both given as subcutaneous injections every six months during the double-blind period lasting up to 32 months with a maximum of 5 years. After this period, all participants enter an open-label extension where everyone receives nucresiran 300 mg every six months. Patients may continue some background therapies as decided by their investigators. Throughout the study, participants will be monitored for mortality and cardiovascular events, including hospitalizations and urgent heart failure visits. Health status and quality of life will be assessed using questionnaires. Safety and efficacy are evaluated through regular assessments during the double-blind phase and ongoing follow-up during the extension. The total study duration extends up to approximately 7 years, including follow-up after the main treatment period.

Age: 18Years - 85YearsAll GendersPhase 3
266 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations